ABSTRACT
Postembolization syndrome (PES) is a common complication after embolic procedures,
and it is a frequent cause of extended inpatient hospital admissions. PES is a self-limited
constellation of symptoms consisting of fevers, unremitting nausea, general malaise,
loss of appetite, and variable abdominal pain following the procedure. Although a
definite cause is unknown, this syndrome is thought to be a result of therapeutic
cytotoxicity, tumor ischemia, and resulting intrahepatic and extrahepatic inflammation.
The authors report a case of PES precipitated by transcatheter intrarterial chemoembolization
of hepatic metastases.
KEYWORDS
Postembolization syndrome (PES) - chemoembolization - hepatocellular carcinoma (HCC)
- transcatheter arterial chemoembolization (TACE) - complications - embolization complications
REFERENCES
- 1
Paye F, Farges O, Dahmane M, Vilgrain V, Flejou J F, Belghiti J.
Cytolysis following chemoembolization for hepatocellular carcinoma.
Br J Surg.
1999;
86
(2)
176-180
- 2
Leung D A, Goin J E, Sickles C, Raskay B J, Soulen M C.
Determinants of postembolization syndrome after hepatic chemoembolization.
J Vasc Interv Radiol.
2001;
12
(3)
321-326
- 3
Ruszniewski P, Malka D.
Hepatic arterial chemoembolization in the management of advanced digestive endocrine
tumors.
Digestion.
2000;
62
(Suppl 1)
79-83
- 4
Lewandowski R J, Mulcahy M F, Kulik L M et al..
Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival
analysis in a 172-patient cohort.
Radiology.
2010;
255
(3)
955-965
- 5
Sakamoto I, Aso N, Nagaoki K M et al..
Complications associated with transcatheter arterial embolization for hepatic tumors.
Radiographics.
1998;
18
(3)
605-619
- 6
Lewandowski R J, Sato K T, Atassi B et al..
Radioembolization with 90Y microspheres: angiographic and technical considerations.
Cardiovasc Intervent Radiol.
2007;
30
(4)
571-592
- 7
Lee K H, Sung K B, Lee D Y, Park S J, Kim K W, Yu J S.
Transcatheter arterial chemoembolization for hepatocellular carcinoma: anatomic and
hemodynamic considerations in the hepatic artery and portal vein.
Radiographics.
2002;
22
(5)
1077-1091
- 8
Chung J W, Park J H, Han J K et al..
Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization.
Radiology.
1996;
198
(1)
33-40
- 9
Castells A, Bruix J, Ayuso C et al..
Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and
clinical meaning of postembolization fever.
J Hepatol.
1995;
22
(4)
410-415
- 10
Romano M, Giojelli A, Tamburrini O, Salvatore M.
Chemoembolization for hepatocellular carcinoma: effect of intraarterial lidocaine
in peri- and post-procedural pain and hospitalization.
Radiol Med (Torino).
2003;
105
(4)
350-355
- 11
Coldwell D M, Loper K A.
Regional anesthesia for hepatic arterial embolization.
Radiology.
1989;
172
(3 Pt 2)
1039-1040
- 12
Rinke A, Müller H H, Schade-Brittinger C PROMID Study Group et al.
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide
LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut
tumors: a report from the PROMID Study Group.
J Clin Oncol.
2009;
27
(28)
4656-4663
Sabeen DhandM.D.
Department of Radiology, Northwestern University
676 North St. Clair Street, Chicago, IL 60611
Email: sabeen.dhand@gmail.com
